Nirsevimab Outperforms Maternal RSV Vaccine in Preventing Infant Hospitalizations
A French cohort study found nirsevimab at birth reduces RSV-related hospitalizations in infants by 22% compared to maternal vaccination. UK data shows the maternal RSV vaccine provides over 80% protection when given at least four weeks before birth. Both strategies aim to protect vulnerable infants during their first months of life.